Reporting of Side Effects Among Stage III and IV Melanoma Patients Treated with Immune Checkpoint Inhibitors

Overview

About this study

This study seeks to understand the treatment experiences and side effect reporting behavior of Stage III and IV melanoma patients who have undergone immunotherapy.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults 18 years of age or older
  • Ability to speak and read English
  • Clinical diagnosis of Stage III or IV melanoma and has been treated with with immunotherapy (checkpoint inhibitors) OR identification as the primary caregiver for a patient with Stage III or IV melanoma who has undergone treatment with immunotherapy (checkpoint inhibitors).

Exclusion Criteria: 

  • Inability to understand the intent of the study
  • Medical condition that would preclude participation in an interview lasting 60 minutes
  • Diagnosis of active psychosis or severe cognitive impairment
  • Family members who are not involved in patients care giving.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Joan Griffin, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions